SuperworthelectroCore price to book ratio ECOR
Market value divided by the book value of the company's net assets, since 2018.
- Today, Oct 23, 2026
- n/m
- not a meaningful number
- Last meaningful
- 34.3×
- Oct 2025
- 8-year median
- 2.8×
- 8-year range
- 0.4× to 38.3×
- Peer median
- 1.9×
electroCore's price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.
It was last meaningful in Oct 2025, at 34.3×.
On the days it had one over the last 8 years, its median was 2.8×, from 0.4× in Mar 2020 to 38.3× in Aug 2025.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2025 | 34.3× | 5.3× | 38.3× |
| 2024 | 11.4× | 3.2× | 11.4× |
| 2023 | 3.2× | 0.7× | 5.2× |
| 2022 | 0.8× | 0.7× | 1.7× |
| 2021 | 1.0× | 1.0× | 4.7× |
| 2020 | 2.5× | 0.4× | 4.8× |
| 2019 | 1.2× | 0.7× | 3.6× |
| 2018 | 2.1× | 1.6× | 5.6× |
Against its peers
Companies in Healthcare nearest electroCore's size, closest first, today.
| Company | Price to book ratio |
|---|---|
| ECORelectroCore | n/m |
| SPROSpero Therapeutics | 1.5× |
| APTAlpha Pro Tech | 0.9× |
| LFVNLifevantage | 2.2× |
| ATNMActinium Pharmaceuticals | 1.6× |
| ICCCImmucell | 3.0× |
| KEQUKewaunee Scientific | 1.3× |
| NEPHNephros | 3.2× |
| PDEXPro DEX | 4.2× |
| PLXProtalix BioTherapeutics | 2.9× |
| NATRNatures Sunshine Products | 1.3× |
| Peer median | 1.9× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on electroCore
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.